therapies. The present invention satisfies this need and provides other advantages as well.

BRIEF SUMMARY

[00011a] In one aspect, the present disclosure refers to a use of a therapeutically effective amount of (i) a composition comprising: an adiponectin peptidomimetic compound and a pharmaceutically acceptable carrier and (ii) Lifitegrast in the manufacture of a medicament for combination therapy of dry eye in a subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6). In one example, there is described a use of a therapeutically effective amount of a composition comprising: an adiponectin peptidomimetic compound and a Lifitegrast and a pharmaceutically acceptable carrier to treat dry eye in the subject in the manufacture of a medicament for treating dry eye in a subject in need thereof.

[00011b] In another aspect, the present disclosure refers to a use of (i) a composition comprising an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and (ii) a therapeutic agent in the manufacture of a medicament for combination therapy of an ocular disease associated with inflammation in the subject need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6). In another example, there is describes a use of a therapeutically effective amount of a composition comprising an adiponectin peptidomimetic compound as disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and a therapeutic agent to treat an ocular disease associated with inflammation in the subject in the manufacture of a medicament for treating the ocular disease associated with inflammation in a subject in need thereof.

[00011c] In yet another aspect, the present disclosure refers to a use of (i) an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and (ii) a therapeutic agent in

the manufacture of a medicament for combination therapy of at least one symptom or clinical sign of dry eye in the subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH2 (SEQ ID NO:6). In one example, there is disclosed a use of: a) a therapeutically effective amount of an adiponectin peptidomimetic compound as disclosed herein or a pharmaceutically acceptable salt thereof and b) a pharmaceutically acceptable carrier; and c) a therapeutic agent to alleviate at least one symptom or clinical sign of dry eye in the subject in the manufacture of a medicament for alleviating at least one symptom or clinical sign of dry eye in a subject in need thereof.

[00011d] In yet another aspect, the present disclosure refers to a use of (i) an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and (ii) a therapeutic agent in the manufacture of a combination therapy of an ocular disease associated with inflammation in the subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH2 (SEQ ID NO:6). In yet another example, there is disclosed a use of a) a therapeutically effective amount of an adiponectin peptidomimetic compound as disclosed herein or a pharmaceutically acceptable salt thereof; and b) a pharmaceutically acceptable carrier; and c) a therapeutic agent to treat an ocular disease associated with inflammation in the subject in the manufacture of a medicament for treating the ocular disease or disorder in a subject in need thereof.

[00012] In one example, provided herein are compositions and methods for treating dry eye in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of composition comprising: an adiponectin peptidomimetic compound and a Lifitegrast and a pharmaceutically acceptable carrier to treat dry eye in the subject.

[00013] In some examples, the composition and therapeutic agent are administered topically, by intravitreal injection, by subconjunctival injection, by conjunctival injection, by intramuscular injection, by subcutaneous injection, by

intravenous injection, by intracameral injection, or by implantation into the subject's eye. In some examples, the dry eye is selected from the group consisting of hypolacrimation, tear deficiency, xerophthalmia, Sjogren's syndrome dry eye, non-Sjogren's syndrome dry eye, keratoconjuctivitis sicca, aqueous tear-deficiency dry eye (ADDE), evaporative dry eye (EDE), environmental dry eye, Stevens- Johnson syndrome, ocular pemphigoid, blepharitis marginal, eyelid-closure failure, sensory nerve paralysis, allergic conjunctivitis-associated dry eye, post-viral conjunctivitis dry eye, post- cataract surgery dry eye, VDT operation-associated dry eye, and contact lens wearing-associated dry eye.

[00014] In some instances, the composition and therapeutic agent are each administered to the subject once a day, two times a day, three times a day, four times a day, or more often (more frequently). In other instances, the composition and therapeutic agent are each administered every other day or less often (less frequently). In some examples, the adiponectin peptidomimetic compound is present in an amount between about 0.0001% (wt) to about 90% (wt) of the final composition. In some examples, the therapeutic agent is present in an amount between about 0.1% to about 20%. In some examples, the composition and therapeutic agent are each in a formulation selected from the

WHAT IS CLAIMED IS:

1. Use of a therapeutically effective amount of (i) a composition comprising: an adiponectin peptidomimetic compound and a pharmaceutically acceptable carrier and (ii) Lifitegrast in the manufacture of a medicament for combination therapy of dry eye in a subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6).

2. The use of claim 1, wherein medicament is to be administered topically, by intravitreal injection, by subconjunctival injection, by conjunctival injection, by intramuscular injection, by subcutaneous injection, by intravenous injection, by intracameral injection, or by implantation into the subject's eye.

3. The use of claim 1, wherein the dry eye is selected from the group consisting of hypolacrimation, tear deficiency, xerophthalmia, Sjogren's syndrome dry eye, non-Sjogren's syndrome dry eye, keratoconjuctivitis sicca, aqueous tear-deficiency dry eye (ADDE), evaporative dry eye (EDE), environmental dry eye, Stevens- Johnson syndrome, ocular pemphigoid blepharitis marginal, eyelid-closure failure, sensory nerve paralysis, allergic conjunctivitis-associated dry eye, post-viral conjunctivitis dry eye, post-cataract surgery dry eye, VDT operation-associated dry eye, and contact lens wearing- associated dry eye.

4. The use of claim 1, wherein the medicament is to be administered to the subject once a day, two times a day, three times a day, four time a day or more often.

5. The use of claim 1, wherein the medicament is to be administered every other day or less often.

6. The use of claim 1, wherein the adiponectin peptidomimetic compound is present in an amount between 0.0001% (wt) to 90% (wt) of the final composition.

7. The use of claim 1, wherein Lifitegrast is to be administered in an amount between 0.1% (wt) to 20% (wt) of the final composition.

8. The use of claim 1, wherein the adiponectin peptidomimetic compound is present in an amount of 0.1% and Lifitegrast is to be administered in an amount of 5% of the final composition.

9. The use of claim 1, wherein the medicament is in a formulation selected from the group consisting of a solution, suspension, syrup, liquid, gel, hydrogel, emulsion, liposome, aerosol, mist, film, suspension, plug, polymer, implant, contact lens, ocular insert, nanoparticle, microparticle, a sustained release formulation, and a formulation suitable for an ocular medical device.

10. The use of claim 1, further comprising a composition comprising cyclosporine, artificial tears, a corticosteroid, an anti-inflammatory agent, or any combination thereof to be administered.

11. Use of (i) a composition comprising an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, and (ii) a therapeutic agent in the manufacture of a medicament for combination therapy of an ocular disease associated with inflammation in the subject need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6).

12. Use of:
(i) an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and
(ii) a therapeutic agent in the manufacture of a medicament for combination therapy of at least one symptom or clinical sign of dry eye in the subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6).

13. Use of:
(i) an adiponectin peptidomimetic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier; and
(ii) a therapeutic agent in the manufacture of a combination therapy of an ocular disease associated with inflammation in the subject in need thereof, wherein the adiponectin peptidomimetic compound is D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH_2 (SEQ ID NO:6).

14. The use of claim 1, wherein the subject presents at least one symptom or clinical sign of dry eye selected from the group consisting of a change in tear secretion, a change in tear clearance, ocular surface damage, corneal epithelial defects, a change in ocular surface cells, a change in tear film stability, a change in tear volume, a change in tear film composition, a change in tear osmolarity, and any combination thereof.